Recruiting
Evaluation of Different Perimetric Grids to Detect Central Visual Field Defect in Glaucoma Patients With Reduce Ganglion Cell Layer Thickness Measured by Spectral Domain OCT.
The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.
ClinicalTrials.gov IDNCT06227611
PhaseNot Applicable
Enrollment16
SponsorFondazione G.B. Bietti, IRCCS
Age18 Years
SexALL
Conditions studied
Glaucoma
About this study
The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.
Primary outcomes
- the agreement between 10-2 HFA and 24-2c HFA in detecting central visual field defect (12 month)
Eligibility information
Inclusion Criteria:
* glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness
Exclusion Criteria:
* age\<18 years
* unable to read, understand and sign the written informed consent
* unable to perform visual field test
* advanced glaucoma with C/D\>0.7
* other causes of optic neuropathies
* retinal or macular diseases
* lens or corneal opacities
* spherical refractive defect \>± 6D
* cylindric refractive defect \>± 3D
Study locations
- IRCCS-Fondazione GB Bietti, Rome, Italy
- University of Rome Tor Vergata, Rome, Italy
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-28.